Corcept Therapeutics Incorporated (CORT)
After hours:
| Previous close | 19.47 |
| Open | 19.46 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's range | 19.29 - 20.38 |
| 52-week range | 15.83 - 25.68 |
| Volume | |
| Avg. volume | 985,243 |
| Market cap | 2.152B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 22.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2022. Financial Results Revenue of $93.7 million, compared to $79.4 million in first quarter 2021Reiterated 2022 revenue guidance
- GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to Join
- GlobeNewswire
Corcept Therapeutics Announces Appointment of Three Senior Leaders
Key Hires Bring Diverse Expertise to Commercial and Development InitiativesMENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn,
